ArticleBMC gastroenterology2026
Mid-esophageal mucosal impedance reflects mucosal integrity and phenotypes refractory reflux-like symptoms.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRefractory reflux-like symptoms (rRLS) are frequently encountered in clinical practice and often reflect heterogeneous underlying mechanisms beyond acid exposure alone. Esophageal mucosal impedance has emerged as a marker of mucosal integrity, yet its role in phenotyping rRLS remains incompletely defined.
methodsIn this retrospective study, adult patients with reflux-like symptoms who underwent multichannel intraluminal impedance-pH monitoring and high-resolution manometry were enrolled. Patients exhibiting persistent reflux-like symptoms despite ≥ 8 weeks of double-dose PPI therapy were defined as having rRLS. Baseline impedance (BI) and mean nocturnal baseline impedance (MNBI) were assessed at three esophageal levels, with particular focus on the mid-esophagus (9 cm above the lower esophageal sphincter). Among patients with refractory symptoms, final diagnoses were established using clinical evaluation, endoscopy, impedance-pH monitoring, and manometry, allowing classification into refractory gastroesophageal reflux disease (GERD), functional heartburn/reflux hypersensitivity (FH/FES) and esophageal structural or functional abnormalities (ESFA).
resultsAmong 165 patients, 73 (44.2%) exhibited rRLS. BI at the mid-esophageal level was significantly lower in refractory compared with non-refractory patients, whereas impedance values at proximal and distal levels showed no significant differences. In refractory patients, MNBI at the mid-esophagus differed significantly across diagnostic phenotypes. Lower MNBI values were associated with esophageal structural or functional abnormalities, while higher values were more frequently observed in functional heartburn or reflux hypersensitivity.
conclusionsMid-esophageal mucosal impedance reflects impairment of mucosal integrity and may contribute to the physiological phenotyping of patients with rRLS. Location-specific impedance assessment could serve as a complementary tool to conventional reflux testing, aiding in mechanism-based classification. However, it should not be used in isolation to guide therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.